IPP Bureau
Aesthetic Revolution: Global study reveals patients demand personalised, long-term beauty plans
By IPP Bureau - March 21, 2026
The company, part of pharma powerhouse AbbVie, will showcase the findings—and the next evolution of its AA Signature framework—at AMWC 2026 in Monaco,
Sakura Finetek and Hamamatsu forge alliance to transform digital pathology workflow
By IPP Bureau - March 21, 2026
Both companies say the collaboration is driven by a shared mission to improve patient outcomes by aligning every step of the diagnostic process
Dr. Reddy’s Laboratories launches India’s first DCGI-approved Semaglutide injection ‘Obeda’ for type 2 diabetes
By IPP Bureau - March 21, 2026
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
Iberia Pharmaceuticals scores big with KeyCi launch, signals shift towards science-backed skincare
By IPP Bureau - March 21, 2026
KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval
Pfizer warns shareholders against Tutanota’s mini-tender offer
By IPP Bureau - March 21, 2026
Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer
Bristol Myers Squibb scores major win with new Opdivo nods for Hodgkin Lymphoma in US, EU
By IPP Bureau - March 21, 2026
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
Touchlight & NEB launch game-changing benchtop DNA kit
By IPP Bureau - March 20, 2026
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
MedRabbits launches integrated clinic to revolutionize patient care
By IPP Bureau - March 20, 2026
Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals
By IPP Bureau - March 20, 2026
The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes
Viva Biotech supercharges AI-driven drug discovery with NVIDIA tech
By IPP Bureau - March 20, 2026
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
Roche breaks lab barriers as FDA clears mass spec tests for wider use
By IPP Bureau - March 20, 2026
The newly classified assays join Roche’s Ionify 25-Hydroxy Vitamin D total assay in a growing U.S. portfolio
SK bioscience bags fresh backing to accelerate fight against respiratory disease
By IPP Bureau - March 20, 2026
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
NIPER Raebareli–Roche tie-up signals big push for India’s pharma innovation future
By IPP Bureau - March 20, 2026
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
Pfizer reports breakthrough in advanced prostate cancer with TALZENNA Plus XTANDI
By IPP Bureau - March 20, 2026
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
